Analysis of population pharmacokinetic data using NONMEM and WinBUGS

Journal of Biopharmaceutical Statistics

Volumn 15, Issue 1, 2005, Pages 53-73

  Duffull, Stephen B ^a   Kirkpatrick, Carl M J ^a   Green, Bruce ^a   Holford, Nicholas H G ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bayesian; MCMC; NONMEM; Pharmacokinetics; Population analysis; WinBUGS

Indexed keywords

ENOXAPARIN; GENTAMICIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONCENTRATION RESPONSE; COVARIANCE; DATA ANALYSIS; DOSE TIME EFFECT RELATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN CARE; NONLINEAR MIXED EFFECTS MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; STATISTICAL MODEL;

BAYES THEOREM; DATABASE MANAGEMENT SYSTEMS; DATABASES, FACTUAL; ENOXAPARIN; GENTAMICINS; HUMANS; INFANT, NEWBORN; MONTE CARLO METHOD; POPULATION SURVEILLANCE; SOFTWARE;

EID: 12344273084     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-200040824     Document Type: Article

References (28)

1. Anon (1999). Guidance for Industry Population Pharmacokinetics. Rockeville, Maryland: FDA.
2. Aarons, L. (1999). Software for population pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 36(4):255-264.
3. Best, N. G., Tan, K. K., Gilks, W. R., Spiegelhalter, D. J. (1995). Estimation of population pharmacokinetics using the Gibbs sampler. J. Pharmacokinet. Biopharm. 23(4): 407-435.
4. Gelman, A. (1995). Bayesian Data Analysis. London: Chapman & Hall.
5. Geman, S., Geman, D. (1984). Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEEE Trans. Pattern Anal. Mach. Intell. 6:721-741.
6. Gilks, W. R., Richardson, S., Spiegelhalter, D. (1996). Markov Chain Monte Carlo in practice. 1st ed. Boca Raton: Chapman & Hall/CRC.
7. Girard, P., Blaschke, T. F., Kastrissios, H., Sheiner, L. B. (1998). A Markov mixed effect regression model for drug compliance. Stat. Med. 17(20):2313-2333.
8. Gisleskog, P. O., Karlsson, M. O., Beal, S. L. (2002). Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29:473-505.
9. Green, B., Duffull, S. B. (2003). Development of a dosing strategy for enoxaparin in obese patients. Br. J. Clin. Pharmacol. 59:96-103.
10. Hastings, W. K. (1970). Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57(1):97-109.
11. Jonsson, F., Johanson, G. (2003). The Bayesian population approach to physiological toxicokinetic-toxicodynamic models-an example using the MCSim software. Toxicol Lett. 138(1-2):143-150.
12. Lunn, D. J., Aarons, L. J. (1997). Markov chain monte carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Appl. Stat. 46(1):73-91.
13. Lunn, D. J., Aarons, L. (1998). The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis. J. Pharmacokinet. Biopharm. 26(1):47-74.
14. Lunn, D. J., Wakefield, J., Thomas, A., Best, N., Spiegelhalter, D. (1999). PKBugs User Guide. Vol Version 1.1. London: Imperial College.
15. Lunn, D. J., Best, N., Thomas, A., Wakefield, J., Spiegelhalter, D. (2002). Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokinet. Pharmacodyn. 29(3):271-307.
16. Merle, Y., Tod, M. (2001). Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J. Pharmacokinet. Pharmacodyn. 28(4):363-388.
17. Press, W. T., Teukolsky, S. A., Vetterling, W. T., Flannery, B. P. (1992). Numerical Recipes in Fortran 77. The Art of Scientific Computing. Vol. 1. 2nd ed. Cambridge: Cambridge University Press.
18. Racine-Poon, A. (1998). Statistical methods for population pharmacokinetic modelling. Stat. Methods Med. Res. 7:63-84.
19. Schoemaker, R. C., Cohen, A. F. (1996). Estimating impossible curves using NONMEM. Br. J. Clin. Pharmacol. 42(3):283-290.
20. Sheiner, L. B., Beal, S. L. (1980). Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8(6):553-571.
21. Spiegelhalter, D., Myles, J. P., Jones, D. R., Abrams, K. R. (1999). An introduction to bayesian methods in health technology. BMJ. 319:508-512.
22. Spiegelhalter, D., Thomas, A., Best, N. (2000). WinBUGS Version 1.3 User Manual. Vol Version 1.3. London: Imperial College.
23. Stickland, M. D., Kirkpatrick, C. M., Begg, E. J., Duffull, S. B., Oddie, S. J., Darlow, B. A. (2001). An extended interval dosing method for gentamicin in neonates. J. Antimicrob. Chemother. 48(6):887-893.
24. Tierney, L. (1994). Markov chains for exploring posterior distributions. Ann. Stat. 22(4): 1701-1762.
25. Wakefield, J. (1996). The Bayesian analysis of population pharmacokinetic models. JASA 91(433):62-75.
26. Wakefield, J., Racine-Poon, A. (1995). An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Stat. Med. 14:971-986.
27. Wakefield, J., Smith, A. F. M., Racine-Poon, A., Gelfand, A. E. (1994). Bayesian analysis of linear and non-linear population models by using the Gibbs sampler. Appl. Stat. 43(1):201-221.
28. Yano, Y., Beal, S. L., Sheiner, L. B. (2001). Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Phannacodyn. 28(2):171-192.